Bevacizumab biosimilar(Dr. Reddy's Laboratories)

贝伐珠单抗生物类似药 (Dr. Reddy's Laboratories)

Report date: 2024/03/26 17:58:49

Base Information

Drug NameBevacizumab biosimilar(Dr. Reddy's Laboratories)
Drug Alias Name贝伐赛珠单抗生物仿制药 (Dr. Reddy's Laboratories)Bevacizumab (Dr. Reddy's Laboratories)Bevacizumabum (Dr. Reddy's Laboratories)贝伐人源化单抗生物仿制药 (Dr. Reddy's Laboratories)贝伐单抗生物仿制药 (Dr. Reddy's Laboratories) +[9] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2019/08/19
Country/TerritoryUnited KingdomIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDr.Reddy's Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDr.Reddy's Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A